JTL-T-01
Pre-clinical- Indications
- Osteoarthritis
Company intelligence / Profile preview
The company’s flagship product, MiniTC®, has received FDA clearance and CE Mark approval. It enables point-of-care preparation of autologous microfat with demonstrated safety and effectiveness in pain management, orthopedics, aesthetics, wound healing, and more. Clinical experience supports its use with improved efficiency over traditional methods. Their first injectable biologic program for osteoarthritis has regulatory clearance as a device-based therapy.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jointechlabs.